Introduction {#s1}
============

*SHOX* (NM_000451.3) encodes a transcription factor exclusively expressed in the developing limb and pharyngeal arch in the human embryo ([@r1]). Heterozygous mutations of *SHOX* lead to Leri-Weill dyschondrosteosis characterized by wrist deformity and mesomelic short stature (LWD; OMIM \#249700), as well as idiopathic short stature without apparent skeletal malformations (ISS; OMIM \# 300582) ([@r2],[@r3],[@r4]). Less specific skeletal changes such as high arched palate, short metacarpals, scoliosis, and micrognathia have also been described in patients with *SHOX* deficiency ([@r5]). Previous studies have shown that *SHOX* deficiency accounts for approximately 80% and 2--16% of genetic causes of LWD and ISS, respectively ([@r5],[@r6],[@r7],[@r8]). Furthermore, haploinsufficiency of *SHOX* represents the major cause of growth failure in patients with Turner syndrome ([@r9]). Thus, *SHOX* deficiency is a clinically important condition, particularly in the field of pediatric endocrinology and orthopedics. This review article introduces our current understanding of the causative mechanisms and phenotypic characteristics of SHOX-associated skeletal malformations.

Molecular Basis of *SHOX* Deficiency {#s2}
====================================

*SHOX* resides in the short arm pseudoautosomal region of the X and Y chromosomes (PAR1) and escapes X inactivation ([@r2]). Thus, although *SHOX* is located on the sex chromosomes, molecular defects of *SHOX* are inherited in an autosomal dominant manner. To date, several point mutations in the *SHOX*-coding exons and submicroscopic deletions encompassing the coding region and/or the upstream or downstream enhancer regions have been identified in more than 200 patients with LWD or ISS ([@r5],[@r6],[@r7],[@r8],[@r9]). Previously reported *SHOX* mutations are listed in the SHOX Mutation Database (http://hyg-serv-01.hyg.uni-heidelberg.de/lovd/index.php?select_db=SHOX) ([@r10]). The precise position of the *SHOX* enhancers remains to be determined, although the upstream and downstream enhancers have been mapped to a \~300 kb region \~95 kb upstream and an \~30 kb region \~250 kb downstream from the start codon, respectively ([@r11],[@r12],[@r13]). Deletions involving the coding and/or downstream enhancer regions account for about 60% of Japanese LWD patients ([@r14]), and those affecting the downstream enhancer regions are the major genetic causes in Spanish patients ([@r15]). High recombination frequency and the abundant presence of repeat sequences in PAR1 likely play a role in the development of submicroscopic genomic rearrangements involving *SHOX* ([@r14]).

Skeletal Deformity in Patients with *SHOX* Deficiency {#s3}
=====================================================

The most characteristic feature in patients with *SHOX* deficiency is Madelung deformity, a cluster of anatomical changes in the forearm including bowing and shortening of the radius, prominence of the ulnar head and palmar and ulnar deviation ("pyramidal configuration") of the carpal bones ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Madelung deformity in a female patient with *SHOX* deficiency. Upper panel: appearance of the forearm. Prominence of the distal ulna is shown. Lower panel: radiographic findings. Shortening and bowing of the radius and dorsal subluxation of the ulnar head are shown. and [Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Forearm three-dimensional computed tomography of a female patient with *SHOX* deficiency. Significant findings include shortening of the radius, pyramidal configuration of the carpal bones and dorsal subluxation of the ulna in addition to severely disturbed structural organization of the elbow joint.) ([@r16]). Clinical manifestations induced by Madelung deformity include wrist pain, deformation and limited joint motion ([@r16], [@r17]). Radiological findings of Madelung deformity include the absence or narrowing of the ulnar portion of the distal radial physis, anterior bowing of the radial shaft and dorsal subluxation of the ulnar head ([@r17], [@r18]). Several additional skeletal changes such as triangularization of the distal radial epiphysis have been associated with Madelung deformity ([@r19]). In patients with severe Madelung deformity, the structural organization of the elbow joint is also disrupted ([Fig. 2](#fig_002){ref-type="fig"}).

Previous studies have suggested that the primary lesion of Madelung deformity is the premature epiphyseal fusion at the volar-ulnar portion of the radial growth plate ([@r20]). Impaired growth of the radius due to the early epiphyseal fusion, in combination with relatively preserved growth of the ulna, appears to underlie the characteristic deformity ([@r18], [@r21]). The appearance of the wrist varies among patients and probably depends on the fusion position along the anterior-posterior axis of the radial epiphysis ([@r22]).

Although Madelung deformity usually occurs as a result of *SHOX* deficiency, it can also take place as a component of other congenital disorders such as multiple exostoses syndrome, multiple epiphyseal dysplasia and dysostosis multiplex of mucopolysaccharidosis ([@r23]). Madelung-like deformity has also been observed in patients with pseudohypoparathyroidism type 1b ([@r24]). In addition, Madelung deformity can occur as a change secondary to injury and infection ([@r19]). When Madelung deformity is accompanied by short stature and mesomelic shorting of the limbs, it is referred to as LWD. The mesomelic short stature of LWD can be explained as a result of impaired linear growth of the radius, ulna, tibia and fibula. A decreased extremity/trunk ratio with a fairly preserved sitting height and head circumference is a characteristic auxological finding of patients with LWD ([@r5], [@r25]). Rappold et al. developed a phenotype scoring system for screening of individuals with possible *SHOX* deficiency from patients with short stature ([@r8]). They suggested the following eight clinical features as indicators for *SHOX* deficiency: arm span/height ratio, sitting height/height ratio, body mass index, cubitus valgus, short forearm, bowing of the forearm, muscular hypertrophy and dislocation of the ulna. Although *SHOX* deficiency is the only condition that has been implicated in LWD, *SHOX* abnormalities have been detected only in 50--90% of patients with LWD ([@r5]). It remains currently unknown whether LWD patients with apparently normal *SHOX* alleles have mutations in the regulatory regions of *SHOX* or in a hitherto unidentified gene involved in skeletal development.

Changes in Bone Geometry andBone Mineral Density {#s4}
================================================

Using peripheral quantitative computed tomography of the forearm, Soucek *et al.* investigated bone mineral density and bone geometry in 10 prepubertal patients with *SHOX* deficiency and 22 patients with Turner syndrome ([@r26]). They found that patients of both groups had a thin bone cortex and an enlarged total bone area at the diaphysis of the radius compared with control individuals. On the other hand, these patients had a normal trabecular bone mineral density and bone strength index. Soucek *et al.* proposed that the skeletal changes observed in patients with *SHOX* deficiency are attributable to an adjustment of the long bones with a disrupted cortex to the mechanical loading that aims to increase bone strength.

Histopathological Changes {#s5}
=========================

Munns *et al.* investigated histopathological findings of the surgically-excised growth plate of the distal radius obtained from two patients with molecularly confirmed *SHOX* deficiency ([@r22]). They found disrupted columnar arrangement of chondrocytes; the normal tandem stacking of mature chondrocytes within columns was replaced by a side-by-side arrangement. Furthermore, the presence of hypertrophic osteoid with micro-enchondromata in the metaphysis suggested aberrant endochondral ossification. Significant expansion of the hypertrophic layer and reduction of the proliferative layer were observed in the growth plate. These data imply that the SHOX protein is required for ordered zonal development of chondrocytes. In this regard, *SHOX* is strongly expressed in terminally differentiated hypertrophic chondrocytes and less obviously in proliferating and reserve chondrocytes ([@r27]). *In vitro* assays with osteosarcoma cells indicated that SHOX induces oxidative stress and activates the intrinsic apoptotic pathway ([@r27]). Thus, it is possible that SHOX plays a critical role in chondrocyte development by regulating the cell cycle and apoptosis of hypertrophic chondrocytes. Indeed, premature epiphyseal fusion in patients with *SHOX* deficiency may reflect a perturbed cell death process in the growth plate. To date, however, the precise mechanism by which SHOX exerts its effect on chondrocyte development remains unknown. Although *in vivo* and *in vitro* assays have indicated that several proteins such as BNP, FGFR3, SOX5, and SOX6 can interact with SHOX ([@r28], [@r29]), the function of SHOX in human tissues has yet to be elucidated.

Formation of an Abnormal Ligament {#s6}
=================================

Vickers and Nielsen identified an abnormal ligament in patients with Madelung deformity ([@r30]). The "Vickers ligament" tethers the lunate to the distal portion of the radius and can have a diameter as large as 8 mm ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.Schematic representation of the Vickers ligament that tethers the lunate to the distal portion of the radius. This ligament seems to consist of hypertrophied connective tissues that form under the mechanical force that arises from asymmetrical growth of the radius and ulna.) ([@r22]). Histological analysis demonstrated that the Vickers ligament is a morphologically normal ligament consisting of collagen and elastin fibers ([@r22]). This ligament is predicted to promote pyramidal configuration of the carpal bones by disturbing the physiological migration of these bones during growth ([@r22]). Furthermore, this ligament may exert an inhibitory effect on linear growth of the radius by compressing its distal epiphysis ([@r18]). Therefore, it is possible that the Vickers ligament constitutes an essential factor in the development of Madelung deformity. Although the process by which the Vickers ligament forms has yet to be clarified, this ligament is regarded as a secondary change of the forearm deformity ([@r30], [@r31]). Actually, the ligament seems to consist of hypertrophied connective tissues that form under a mechanical force that arises from asymmetrical growth of the radius and ulna.

Recent advancements in high-resolution magnetic resonance imaging have enabled early detection of the Vickers ligament ([@r31]). Previous studies have indicated that surgical removal of the Vickers ligament in combination with dome osteotomy is beneficial to patients with Madelung deformity; Harley *et al.* reported that these surgical interventions effectively improved the clinical features of adolescent patients with Madelung deformity ([@r21]), while Steinman *et al.* showed that these interventions can provide long-term correction of the wrist deformity ([@r16]). However, since the number of treated patients was small, further studies are necessary to validate these findings.

Phenotypic Determinants {#s7}
=======================

Skeletal changes of *SHOX* deficiency tend to be more severe in adult females than in children or adult males ([@r5]). Obvious Madelung deformity is rare in prepubertal patients, although decreased extremity/trunk ratios and subtle skeletal changes are observed in the majority of children with *SHOX* deficiency ([@r5], [@r32], [@r33]). These data can be explained by assuming that estrogens exert a deleterious effect on skeletal formation in patients with *SHOX* abnormalities. Since estrogens induce physiological skeletal maturation in both sexes ([@r34]), they may also enhance premature epiphyseal fusion in patients with *SHOX* deficiency. Consistent with this, severe Madelung deformity is rarely seen in Turner females in whom ovarian function is frequently impaired ([@r35]). Furthermore, a longitudinal study of a female patient with *SHOX* deficiency and normal ovarian function showed age-appropriate skeletal maturation before puberty and rapidly advanced bone age during puberty ([@r36]). On the other hand, since Soucek et al. revealed a significant difference in bone geometry between prepubertal patients with the 46,XX karyotype and prepubertal Turner females, it is likely that some factors other than estrogens may also underlie relatively mild skeletal features in Turner females ([@r26]). Soucek et al. suggested karyotype mosaicism as one of the possible candidates for such factors ([@r26]). It is known that the karyotype of Turner females is heterogeneous and includes 45,X/46,XX. Since two normal *SHOX* alleles are present in a certain percentage of cells in females with the 45,X/46,XX karyotype, this may lead to relatively well preserved skeletal structures in such patients.

Mutation types may affect the phenotypic severity of *SHOX* deficiency. It has been proposed that molecular defects involving only the enhancer regions are associated with broader phenotypic variation than deletions/mutations affecting the coding exons; Chen et al. have described more severe skeletal changes in patients with enhancer deletions than in those with mutations/deletions affecting the coding exons ([@r37]), while Rosilio et al. reported relatively mild phenotypes in patients with enhancer deletions ([@r7]). On the other hand, no apparent genotype-phenotype correlation has been reported for *SHOX* intragenic mutations/deletions ([@r8]).

Conclusion {#s8}
==========

Recent studies have indicated that *SHOX* deficiency leads to premature epiphyseal fusion at the distal radius, possibly by disturbing programmed cell death of hypertrophic chondrocytes. In addition, the formation of an aberrant ligament tethering the lunate and radius appears to play a role in the development of Madelung deformity. Blood estrogen levels and mutation types have been proposed as phenotypic determinants of *SHOX* deficiency, although other unknown factors may also modify the clinical severity of this condition.
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